152 related articles for article (PubMed ID: 12665524)
21. Mapping the interaction between high molecular mass kininogen and the urokinase plasminogen activator receptor.
Mahdi F; Shariat-Madar Z; Kuo A; Carinato M; Cines DB; Schmaier AH
J Biol Chem; 2004 Apr; 279(16):16621-8. PubMed ID: 14764580
[TBL] [Abstract][Full Text] [Related]
22. Crystallization of soluble urokinase receptor (suPAR) in complex with urokinase amino-terminal fragment (1-143).
Huang M; Mazar AP; Parry G; Higazi AA; Kuo A; Cines DB
Acta Crystallogr D Biol Crystallogr; 2005 Jun; 61(Pt 6):697-700. PubMed ID: 15930623
[TBL] [Abstract][Full Text] [Related]
23. Structure and function of the human Gly1619Arg polymorphism of M6P/IGF2R domain 11 implicated in IGF2 dependent growth.
Rezgui D; Williams C; Savage SA; Prince SN; Zaccheo OJ; Jones EY; Crump MP; Hassan AB
J Mol Endocrinol; 2009 Apr; 42(4):341-56. PubMed ID: 19208780
[TBL] [Abstract][Full Text] [Related]
24. The kringle stabilizes urokinase binding to the urokinase receptor.
Bdeir K; Kuo A; Sachais BS; Rux AH; Bdeir Y; Mazar A; Higazi AA; Cines DB
Blood; 2003 Nov; 102(10):3600-8. PubMed ID: 12881310
[TBL] [Abstract][Full Text] [Related]
25. Recognition of Dictyostelium discoideum lysosomal enzymes is conferred by the amino-terminal carbohydrate binding site of the insulin-like growth factor II/mannose 6-phosphate receptor.
Marron-Terada PG; Hancock MK; Haskins DJ; Dahms NM
Biochemistry; 2000 Mar; 39(9):2243-53. PubMed ID: 10694390
[TBL] [Abstract][Full Text] [Related]
26. Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding.
Quax PH; Grimbergen JM; Lansink M; Bakker AH; Blatter MC; Belin D; van Hinsbergh VW; Verheijen JH
Arterioscler Thromb Vasc Biol; 1998 May; 18(5):693-701. PubMed ID: 9598826
[TBL] [Abstract][Full Text] [Related]
27. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.
Ploug M; Ostergaard S; Hansen LB; Holm A; Danø K
Biochemistry; 1998 Mar; 37(11):3612-22. PubMed ID: 9521680
[TBL] [Abstract][Full Text] [Related]
28. Urokinase regulates vitronectin binding by controlling urokinase receptor oligomerization.
Sidenius N; Andolfo A; Fesce R; Blasi F
J Biol Chem; 2002 Aug; 277(31):27982-90. PubMed ID: 12034711
[TBL] [Abstract][Full Text] [Related]
29. The bovine mannose 6-phosphate/insulin-like growth factor II receptor. Localization of mannose 6-phosphate binding sites to domains 1-3 and 7-11 of the extracytoplasmic region.
Westlund B; Dahms NM; Kornfeld S
J Biol Chem; 1991 Dec; 266(34):23233-9. PubMed ID: 1660469
[TBL] [Abstract][Full Text] [Related]
30. Sequences within domain II of the urokinase receptor critical for differential ligand recognition.
Li Y; Lawrence DA; Zhang L
J Biol Chem; 2003 Aug; 278(32):29925-32. PubMed ID: 12761227
[TBL] [Abstract][Full Text] [Related]
31. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
Mizukami IF; Todd RF
J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
[TBL] [Abstract][Full Text] [Related]
32. Soluble human urokinase receptor is composed of two active units.
Higazi AA; Mazar A; Wang J; Quan N; Griffin R; Reilly R; Henkin J; Cines DB
J Biol Chem; 1997 Feb; 272(8):5348-53. PubMed ID: 9030610
[TBL] [Abstract][Full Text] [Related]
33. Ligand binding regions in the receptor for urokinase-type plasminogen activator.
Liang OD; Chavakis T; Kanse SM; Preissner KT
J Biol Chem; 2001 Aug; 276(31):28946-53. PubMed ID: 11501527
[TBL] [Abstract][Full Text] [Related]
34. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.
Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA
J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549
[TBL] [Abstract][Full Text] [Related]
35. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
36. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site.
Ploug M
Biochemistry; 1998 Nov; 37(47):16494-505. PubMed ID: 9843416
[TBL] [Abstract][Full Text] [Related]
37. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
38. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region.
Gårdsvoll H; Ploug M
J Biol Chem; 2007 May; 282(18):13561-72. PubMed ID: 17355965
[TBL] [Abstract][Full Text] [Related]
39. Intermolecular contact regions in urokinase plasminogen activator receptor.
Liang OD; Bdeir K; Matz RL; Chavakis T; Preissner KT
J Biochem; 2003 Nov; 134(5):661-6. PubMed ID: 14688231
[TBL] [Abstract][Full Text] [Related]
40. Domain 5 of the cation-independent mannose 6-phosphate receptor preferentially binds phosphodiesters (mannose 6-phosphate N-acetylglucosamine ester).
Chavez CA; Bohnsack RN; Kudo M; Gotschall RR; Canfield WM; Dahms NM
Biochemistry; 2007 Nov; 46(44):12604-17. PubMed ID: 17927214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
